Compare RHP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHP | TGTX |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.5B |
| IPO Year | 1991 | 1995 |
| Metric | RHP | TGTX |
|---|---|---|
| Price | $92.06 | $30.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $109.33 | $54.75 |
| AVG Volume (30 Days) | 454.6K | ★ 1.5M |
| Earning Date | 02-23-2026 | 11-03-2025 |
| Dividend Yield | ★ 5.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.77 | 2.78 |
| Revenue | ★ $2,486,871,000.00 | $531,898,000.00 |
| Revenue This Year | $10.49 | $87.88 |
| Revenue Next Year | $8.16 | $48.75 |
| P/E Ratio | $24.97 | ★ $10.59 |
| Revenue Growth | 6.48 | ★ 100.88 |
| 52 Week Low | $76.27 | $25.28 |
| 52 Week High | $108.42 | $46.48 |
| Indicator | RHP | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 46.53 |
| Support Level | $93.62 | $28.90 |
| Resistance Level | $95.86 | $31.37 |
| Average True Range (ATR) | 1.83 | 0.90 |
| MACD | -0.67 | -0.04 |
| Stochastic Oscillator | 16.28 | 53.61 |
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.